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1. Introduction 
In human clinical trials, ethical considerations for study subjects override the scientific 
requirements of trial design. Noncompliance with an intervention or study procedure for 
ethical reasons is thus inevitable in practice (Piantadosi, 1997). 
The Coronary Drug Project (CDP) trial (CDP Research Group, 1980) was a typical example 
of trials with noncompliance. The CDP trial was a large, double-blinded, randomized trial 
testing the effect of the cholesterol-lowering drug, clofibrate, on mortality. Patients were 
randomly assigned to the clofibrate or placebo groups and were followed for at least 5 years, 
documenting clinic visits and examinations. During each 4-month follow-up visit, the 
physician assessed compliance by counting or estimating the number of capsules returned 
by the patients. In the protocol, good compliers were defined as patients taking more than 
80% of the prescribed treatment. Table 1 summarizes the incidence of death during the  
5-year follow-up period, based on the treatment assigned and compliance status. Patients 
who left the trial before the end of the 5-year follow-up period were excluded. 
 
Group 
No. of 
patients 
Deaths 
Compliance 
status 
No. of 
patients 
Deaths 
Clofibrate 1065 194 More than 80% 708 106 
   Less than 80% 357 88 
Placebo 2695 523 More than 80% 1813 274 
   Less than 80% 882 249 
Totals 3760 717    
Table 1. The compliance status and incidence of death during a 5-year follow-up period in 
the CDP trial. 
In the clofibrate group, 708 patients were considered good compliers; 106 died during the 
follow-up period. There were 357 patients considered poor compliers; 88 died. Comparing the 
compliance status of the proportion of patients that died yields 106/708 – 88/357 = –9.68%. 
From this result, clofibrate seems to have been beneficial. However, when we make the same 
comparison for the placebo group, it yields 274/1813 – 249/882 = –13.12%. Surprisingly, we 
obtain the result that the placebo was more beneficial than clofibrate. However, nobody would 
interpret the result as being that the placebo had the effect of decreasing death. 
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Which subgroups to compare to estimate the treatment effect correctly is an important 
problem. From the viewpoint of treatment compliance, it is considered best to compare the 
proportion of deaths for the compliers in each group: 106/708 – 274/1813 = –0.14%. This 
comparison is called the per-protocol (PP) analysis. The PP analysis generally yields biased 
estimates of treatment effects, because whether patients comply with the assigned treatment 
is not randomized and several factors may affect it. This problem can be avoided by 
intention-to-treat (ITT) analysis, in which patients are analyzed according to the assigned 
treatment regardless of the treatment actually received (Fisher et al., 1990; Lee et al., 1991): 
194/1065 – 523/2695 = –1.19%. The ITT estimate may represent the effect of the treatment 
intended, but generally does not represent the treatment effect itself (Schwartz & Lellouch, 
1967; Sheiner & Rubin, 1995). 
Noncompliance data may be obtained from actual clinical trials, as in the CDP trial. To 
estimate the treatment effect correctly from such data, we should consider the expected 
outcomes if all patients had received the test treatment and the control, and compare them. 
The effect yielded from such a comparison is called the average causal effect (ACE) (Robins 
& Tsiatis, 1991; Robins & Greenland, 1994). Several researchers have discussed methodology 
to estimate ACE (Pearl, 2000; Manski, 2003; Sato, 2006), but as yet, no standard methodology 
has been developed. Nevertheless, we can derive bounds on ACE using the deterministic 
causal model (e.g., Pearl, 1995; Cai et al., 2007; Chiba, 2009b). In this chapter, we discuss how 
estimates from major analyses, such as ITT and PP, are biased and present bounds on ACE 
under certain assumptions. 
To achieve these objectives, this chapter is organized as follows. In Section 2, notation and 
definitions are provided. Sections 3 and 4 discuss noncompliance by switching the 
treatment, which, in contrast to the CDP trial, means that non-compliers in a sub-population 
assigned to treatment A receive treatment B and those assigned to treatment B receive 
treatment A. We discuss biases from major analyses such as ITT and PP in Section 3, and 
discuss the bounds on ACE in Section 4. Section 5 discusses noncompliance by receiving no 
treatment, as in the CDP trial. As in many publications, the instrumental variable (IV) 
assumption is used in these sections, but this assumption is relaxed in Section 6. Finally, 
Section 7 offers some concluding remarks. The derivations of equations and inequalities 
presented in this chapter are outlined in Section 8. 
2. Notation and definitions 
In the following sections, R is the randomization indicator, where R = 2 for subjects 
randomized to the test treatment and R = 1 for subjects randomized to the control. Similarly, 
X indicates actual (received) treatment that may not be randomized under protocol 
violations such as noncompliance, where X = 2 for subjects who received the test treatment, 
X = 1 for subjects who received the control, and X = 0 for subjects who received no 
treatment. The observed outcome is Y and YX=x is the counterfactual value (or equally 
potential outcome) of Y if treatment X was set to x (Rubin, 1974, 1978, 1990). ACE is defined 
as ACE ≡ E(YX=2) – E(YX=1). Note that ITT and PP estimators are represented by ITT ≡ E(Y|R 
= 2) – E(Y|R = 1) and PP ≡ E(Y|X = 2, R = 2) – E(Y|X = 1, R = 1), respectively. Furthermore, 
we use the notation Exr = E(Y|X = x, R = r) and px|r = Pr(X = x|R = r); then, PP ≡ E22 – E11. 
We require the consistency assumption that YX=x = Y for all subjects, so that the value of Y 
that would have been observed if X had been set to what it in fact was is equal to the value 
of Y that was in fact observed. Thus, this assumption indicates that E(YX=x|X = x) = E(Y|X = 
x) and furthermore E(YX=x|X = x, R = r) = E(Y|X = x, R = r) (= Exr). We assume that YX=x is 
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independent from X given R and Z, where Z is a confounder or a set of confounders 
between X and Y. In Sections 3-5, we also require the instrumental variable (IV) assumption, 
which states that the potential outcome YX=x is not affected directly by the treatment 
assignment R; rather, YX=x is influenced only by the treatment actually received (Holland, 
1986; Angrist et al., 1996). Thus, subjects’ potential outcomes are independent of treatment 
assignment and are constant across the sub-populations of subjects assigned to different 
treatment arms. The IV assumption is formalized as follows: 
ASSUMPTION 1: Instrumental variable (IV) 
 E(YX=x|R = 2) = E(YX=x|R = 1). 
This assumption may hold in successfully blinded randomized trials, because subjects are 
not aware of their assigned treatments and so the assigned treatments do not affect the 
potential outcomes. However, this often may not hold in unblinded trials, in which subjects 
are aware of the assigned treatment and this knowledge may affect the potential outcomes, 
and needs to be critically evaluated. Assumption 1 is used in Sections 3-5, but is relaxed in 
Section 6. 
3. Biases of estimates 
In this section and the next section, we discuss noncompliance by switching the treatment, 
which means that non-compliers in a sub-population assigned to treatment A receive 
treatment B and those assigned to treatment B receive treatment A. In this type of 
noncompliance, all subjects have the value X = 1 or 2 (and not X = 0) for both R = 1 and 2. 
Thus, p0|r = 0 and p1|r + p2|r = 1. The derivations of equations in this section are given in 
Section 8.1. 
In this section, we discuss how estimates from major analyses, such as ITT and PP, are 
biased. To do so, we introduce the following R-specific bias factors due to confounding 
between X and Y (Brumback et al, 2004; Chiba et al., 2007): 
ǂr ≡ E(YX=2|X = 2, R = r) – E(YX=2|X = 1, R = r), 
ǃr ≡ E(YX=1|X = 2, R = r) – E(Y X=1|X = 1, R = r), 
where r = 1, 2. ǂr and ǃr are confounding effects that would arise from R-stratified 
comparisons of those with X = 2 versus those with X = 1. When ǂr > 0 and ǃr > 0, E(YX=x|X = 
2, R = r) > E(YX=x|X = 1, R = r), which means that the subjects who received the test 
treatment tend to have larger outcome values than those who received the control, leading 
to positive confounding. Conversely, when ǂr < 0 and ǃr < 0, E(YX=x|X = 2, R = r) < E(YX=x|X 
= 1, R = r), which means that the subjects who received the test treatment tend to have 
smaller outcome values than those who received the control, leading to negative 
confounding. No confounding occurs between X and Y when ǂr = ǃr = 0. 
Under Assumption 1, using ǂr and ǃr, E(YX=2) and E(YX=1) are expressed as: 
 E(YX=2) = E2r – ǂrp1|r, (3.1) 
 E(YX=1) = E1r + ǃrp2|r. (3.2) 
Using these equations, ITT ≡ E(Y|R = 2) – E(Y|R = 1) can be expressed by a function of ACE 
≡ E(YX=2) – E(YX=1) and bias factors: 
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 ITT = ACE + {ǂ2 – (E22 – E12)}p1|2 + {ǃ1 – (E21 – E11)}p2|1. (3.3) 
Thus, the ITT estimator is generally a biased estimator of ACE, and can be unbiased when ǂ2 
= E22 – E12 and ǃ1 = E21 – E11, i.e., E(YX=2|X = x, R = r) = E(YX=1|X = x, R = r) for x ≠ r. This 
equation implies that the ITT estimate can be unbiased when no treatment effect exists for 
all subjects (under the sharp null hypothesis: YX=2 = YX=1 for all subjects). Furthermore, 
equation (3.3) shows that, if we know whether the treatment effect is positive or negative, 
we can know the sign of bias of the ITT estimate. 
Likewise, it can be demonstrated that the PP estimator is generally a biased estimator of 
ACE, because the difference between equation (3.1) with r = 2 and equation (3.2) with r = 1 
derives: 
 PP = ACE + ǂ2p1|2 + ǃ1p2|1. (3.4) 
This equation shows that the PP estimate can be unbiased when ǂ2 = 0 and ǃ1 = 0, which imply 
that whether subjects receive the test treatment or control treatment is randomly determined (no 
confounder exists between X and Y). Furthermore, if we know the common sign of confounding 
effects (the common signs of ǂr and ǃr), we can know the sign of the bias of the PP estimate. 
In addition to the ITT and PP estimators, the IV estimator has been developed (Cuzick et al., 
1997; Greenland, 2000; Hernán & Robins, 2006). The estimate is calculated by the following 
formula: 
IV ≡ {E(Y|R = 2) – E(Y|R = 1)}/(p2|2 – p2|1) 
for p2|2 ≠ p2|1. Although the IV estimator may yield a less biased estimate of ACE, it is also 
generally biased. This is because the IV estimator is expressed using bias factors as follows 
(Chiba, 2010a): 
 IV = ACE – w1(ǂ1 – ǃ1) + w2(ǂ2 – ǃ2), (3.5) 
where wr = p1|rp2|r/(p2|2 – p2|1) and p2|2 ≠ p2|1. Thus, the IV estimate can be unbiased when ǂr 
= ǃr, i.e., E(YX=2 – YX=1|X = 2, R = r) = E(YX=2 – YX=1|X = 1, R = r). Similar to the ITT estimate, 
the IV estimate can also be unbiased when no treatment effect exists for all subjects (under 
the sharp null hypothesis: YX=2 = YX=1 for all subjects). Additionally, the IV estimate can be 
unbiased even when E(YX=2 – YX=1|X = x, R = 2) = E(YX=2 – YX=1|X = x, R = 1) (Robins, 1989). 
Furthermore, as an alternative to the IV estimator, Chiba (2010b) proposed the following 
estimator of ACE: 
IV’ ≡ (E22p1|1 + E12p2|1 – E21p1|2 – E11p2|2)/(p2|2 – p2|1). 
This estimator is also generally a biased estimator of ACE, and the estimate can be unbiased 
under ǂ1 = ǂ2 and ǃ1 = ǃ2, which may be reasonable when the influence of confounding 
between X and Y is equal in both assigned groups. 
4. Bounds on average causal effect 
In randomized trials with noncompliance by switching the treatment, we cannot generally 
estimate ACE in an unbiased manner (Section 3). Thus, in this section, we discuss bounds on 
ACE. We introduce the bounds under some assumptions in Section 4.1, and illustrate them 
by using data from a classic randomized trial in Section 4.2. The derivations of inequalities 
in this section are outlined in Section 8.2. 
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4.1 Assumptions and bounds 
In Section 4.1.1, we introduce bounds on ACE under Assumption 1 only. Because the 
bounds generally have a broad width, we present the bounds with narrower widths by 
adding some plausible assumptions in Sections 4.1.2 and 4.1.3. 
4.1.1 The instrumental variable 
When the outcome Y has a finite range [K0, K1], the bounds on ACE under Assumption 1 are 
as follows (Robins, 1989; Manski, 1990): 
 
0 1|1 21 2|1 11 1|1 1 2|1
0 1|2 22 2|2 12 1|2 1 2|2
1 1|1 21 2|1 11 1|1 0 2|1
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 (4.1) 
Note that K0 = 0 and K1 = 1 in the case of a binary outcome. Furthermore, using a method of 
linear programming in the case of a binary outcome, Balke and Pearl (1997) presented the 
following bounds under Assumption 1 only: 
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(4.2)
 
where Pyx|r = Pr(Y = y, X = x|R = r) (y = 0, 1). Inequality (4.2), which is the bounds on ACE 
having the narrowest width without adding any other assumptions, gives bounds with a 
narrower width than inequality (4.1) in some situations. However, these bounds generally 
have broad widths. Thus, in Sections 4.1.2 and 4.1.3, we derive bounds with narrower 
widths by adding some plausible assumptions. 
4.1.2 The monotone treatment response 
To derive narrower bounds, Manski (1997) presented the following monotone treatment 
response (MTR) assumption: 
ASSUMPTION 2.1: Monotone treatment response (MTR) 
 YX=s ≥ YX=t for all subjects, where s ≥ t. 
For (s, t) = (2, 1), the MTR means that a subject takes a larger outcome value if he/she 
received the test treatment than if he/she received the control. This holds when it is 
apparent that the test treatment has a positive effect. 
Under Assumptions 1 and 2.1, the lower bound on ACE is improved as follows: 
 ACE ≥ max{ITT, –ITT}. (4.3) 
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Thus, we can say that ACE is not less than the ITT estimate when the MTR holds. Note that the 
second and third terms in equation (3.3) are not less than 0 under the MTR, because E(YX=2|X 
= x, R = r) ≥ E(YX=1|X = x, R = r), i.e., ǂ2 ≥ E22 – E12 and ǃ1 ≥ E21 – E11, hold under the MTR. 
Using the reverse sign of the inequality in Assumption 2.1, the following reverse MTR 
(RMTR) assumption can be applied: 
ASSUMPTION 2.2: Reverse monotone treatment response (RMTR) 
 YX=s ≤ YX=t for all subjects, where s ≥ t. 
In contrast to the MTR, for (s, t) = (2, 1), the RMTR means that a subject takes a smaller 
outcome value if he/she received the test treatment than if he/she received the control. This 
holds when it is apparent that the test treatment has a negative effect. Under Assumptions 1 
and 2.2, the upper bound on ACE is improved as ACE ≤ min{ITT, –ITT}, implying that ACE 
is not more than the ITT estimate when the RMTR holds. 
Assumptions 2.1 and 2.2 are very strict assumptions, because the inequalities must hold for 
all subjects. In the case of a binary outcome variable, we can use an alternative assumption 
that is weaker than Assumptions 2.1 and 2.2, but can derive the same bound as those under 
these assumptions. This is introduced below after the concept of principal stratification 
(Frangakis & Rubin, 2002). 
Based on principal stratification, four types of potential outcomes are defined as follows: 
doomed {YX=2 = 1, YX=1 = 1}, which consists of subjects who always experience the event, 
regardless of the treatment received; preventive {YX=2 = 0, YX=1 = 1}, which consists of 
subjects who do not experience the event when they receive the test treatment but do when 
they receive the control; causative {YX=2 = 1, YX=1 = 0}, which consists of subjects who 
experience the event when they receive the test treatment, but not when they receive the 
control; and immune {YX=2 = 0, YX=1 = 0}, which consists of subjects who never experience 
the event, regardless of the treatment received (Greenland & Robins, 1986). Because X and Y 
are binary, the potential outcomes could be any of these four types. Note that Assumption 
2.1 implies that no preventive subject exists: Pr(YX=2 = 0, YA=1 = 1) = 0, because YX=2 = 0 and 
YX=1 = 1 cannot hold simultaneously under YX=2 ≥ YX=1. Likewise, Assumption 2.2 implies 
that no causative subject exists. 
We can obtain inequality (4.3) even under the following assumption (Chiba, 2011): 
ASSUMPTION 3.1 
 Pr(YX=2 = 1, YX=1 = 0|X = x, R = r) ≥ Pr(YX=2 = 0, YX=1 = 1|X = x, R = r). 
This assumption indicates that the number of causative subjects is not less than the number 
of preventive subjects within all strata with X = x and R = r. Thus, Assumption 3.1 is weaker 
than Assumption 2.1, because Assumption 2.1 requires that no preventive subject exists but 
this is not the case for Assumption 3.1. 
Likewise, the following assumption, 3.2, can derive the same upper bound as that under 
Assumption 2.2: 
ASSUMPTION 3.2 
 Pr(YX=2 = 1, YX=1 = 0|X = x, R = r) ≤ Pr(YX=2 = 0, YX=1 = 1|X = x, R = r). 
In contrast to Assumption 3.1, this assumption implies that the number of causative subjects 
is not more than the number of preventive subjects within all strata with X = x and R = r. 
Again, note that Assumption 2.2 implies that no causative subject exists and thus 
Assumption 3.2 is a weaker assumption than Assumption 2.2. 
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4.1.3 The monotone treatment selection 
The other assumption to derive narrower bounds is the following monotone treatment 
selection assumption (Manski & Pepper, 2000; Chiba, 2010c): 
ASSUMPTION 4.1: Monotone treatment selection (MTS)  
E(YX=x|X = s, R = r) ≥ E(YX=x|X = t, R = r) for s ≥ t. 
For (s, t) = (2, 1), the MTS means that subjects who received the test treatment tend to have 
larger outcome values than those who received the control within each study treatment-arm 
subpopulation. For example, when patients with a worse condition prefer to receive the new 
treatment (X = 2), it should be anticipated that the incidence proportion of a bad event (Y = 
1) such as death will be higher, compared with those who receive the standard treatment (X 
= 1); this indicates that the MTS holds. 
Under Assumptions 1 and 4.1, the upper bound on ACE is improved as follows: 
 ACE ≤ min{E21, E22} – max{E11, E12}. (4.4) 
Specifically, when min{E21, E22} = E22 and max{E11, E12} = E11, the upper bound is equal to the 
PP estimator. Thus, ACE is no more than the PP estimate when the MTS holds. Note that 
this is also verified from equation (3.4) because Assumption 4.1 implies that ǂr ≥ 0 and ǃr ≥ 0. 
Similar to the RMTR, the following reverse MTS (RMTS) assumption can be applied: 
ASSUMPTION 4.2: Reverse monotone treatment selection (RMTS) 
E(YX=x|X = s, R = r) ≤ E(YX=x|X = t, R = r) for s ≥ t. 
In contrast to the MTS, for (s, t) = (2, 1), the RMTS means that subjects who received the test 
treatment tend to have smaller outcome values than those who received the control within 
each study treatment-arm subpopulation. The lower bound on ACE under the RMTS is ACE 
≥ max{E21, E22} – min{E11, E12}, implying that ACE is not less than the PP estimate when the 
RMTS holds. 
It is obvious that the combination of Assumptions 2.1 and 4.1 improves both the lower and 
upper bounds: 
max{ITT, –ITT} ≤ ACE ≤ min{E21, E22} – max{E11, E12}. 
Likewise, under the combination of Assumptions 2.2 and 4.2, bounds on ACE are 
 max{E21, E22} – min{E11, E12} ≤ ACE ≤ min{ITT, –ITT}. (4.5) 
These inequalities show that ACE exists between ITT and PP estimates under these 
combinations of assumptions. 
By extending a theory developed in the context of observational studies (VanderWeele, 
2008a; Chiba, 2009a), Chiba (2009b) presented another assumption that derives the same 
upper bound as that under the MTS (Assumption 4.1): 
ASSUMPTION 5.1: Monotone confounding (MC)  
Both E(Y|X = 2, R = r, Z = z) and Pr(X = 2|R = r, Z = z) are non-decreasing or  
non-increasing in z for all r, and the components of Z are independent of each other. 
For an assumption corresponding to the RMTS (Assumption 4.2), Assumption 5.1 is 
changed as follows: 
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ASSUMPTION 5.2: Reverse monotone confounding (RMC) 
 One of E(Y|X = 2, R = r, Z = z) and Pr(X = 2|R = r, Z = z) is non-decreasing and the  
other is non-increasing in z for all r, and the components of Z are independent of each other. 
Although the MTS and MC (RMTS and RMC) give the same upper (lower) bound on ACE, 
the relationship between them has not been clear. In Section 8.2, we demonstrate that the 
MC implies the MTS, but it is unclear whether the converse holds. 
4.2 Application 
For illustration, the assumptions and bounds presented in this section are applied to data 
from the Multiple Risk Factor Intervention Trial (MRFIT) (MRFIT Research Group, 1982). 
The MRFIT was a large field trial to test the effect of a multifactorial intervention program 
on mortality from coronary heart disease (CHD) in middle-aged men with sufficiently high 
risk levels attributed to cigarette smoking, high serum cholesterol, and high blood pressure. 
Intervention consisted of dietary advice on ways to reduce blood cholesterol, smoking 
cessation counseling, and hypertension medication. All subjects were randomly assigned to 
the intervention program or the control group. 
For this illustration, attention is restricted to the effects of cessation of cigarette smoking. This 
restriction follows other studies (Mark & Robins, 1993; Matsui, 2005; Chiba, 2010a) and was 
applied due to the paucity of differences achieved for the other risk factors. Table 2 
summarizes the incidence of subject mortality due to CHD during the 7-year follow-up period 
based on the assigned treatment and the actual subject smoking status 1 year after study entry. 
R represents the assigned group (R = 2 for the test group and R = 1 for the control group), X is 
the actual smoking status 1 year after entry (X = 2 for smoking cessation and X = 1 for 
continued smoking), and Y is the incidence of CHD deaths (Y = 1 for dead and Y = 0 for alive). 
ITT and PP analyses yielded ITT = 69/3833 – 74/3830 = −0.13% and PP = 11/991 – 70/3456 = 
−0.92%, respectively. IV and IV’ estimates were −0.82% and −0.72%, respectively. 
 
Group 
No. of 
subjects 
CHD 
deaths 
Smoking status 
at 1 year 
No. of 
subjects 
CHD 
deaths 
Test 3833 69 Quit 991 11 
   Not quit 2842 58 
Control 3830 74 Quit 374 4 
   Not quit 3456 70 
Totals 7663 143    
Table 2. The status of cigarette smoking and the incidence of mortality due to CHD in the 
MRFIT during a 7-year follow-up period. 
To derive the ACE bounds, it is necessary to discuss whether the assumptions in this section 
hold. It is clear that cessation of cigarette smoking prevents death from CHD. Thus, 
Assumption 2.2 (RMTR: YX=2 ≤ YX=1 for all subjects) holds (i.e., no causative subject, who 
died when they quit smoking but lived when they continued smoking, exists). However, it 
is possible that such subjects do exist, because the stress of quitting smoking might lead to 
CHD and this stress would have been lower if the subject had continued smoking (i.e., a 
causative subject existed). Under this observation, Assumption 2.2 does not hold. However, 
Assumption 3.2 would still hold, because even if a few causative subjects exist, the number 
would be the smallest in the four principal strata. 
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In general, health-conscious individuals may tend not to die from CHD and quit smoking 
compared with individuals who are not health-conscious. Trial subjects would likely have 
had similar tendencies, and subjects who quit smoking would logically tend not to have 
died from CHD. Therefore, it is considered that Assumption 4.2 (RMTS: E(YX=x|X = 2, R = r) 
≤ E(YX=x|X = 1, R = r) for x = 1, 2 and r = 1, 2) is valid. Although Assumption 1 may not hold 
because this trial was an unblinded trial (the details are discussed in Section 6), we here use 
this assumption for illustrative purposes. 
The arguments presented above demonstrate that Assumptions 3.2 and 4.2 can be assumed. 
Thus, from inequality (4.5), the bounds on ACE become −0.92% ≤ ACE ≤ −0.13%. This result 
indicates that quitting smoking would prevent death from CHD. Note that the bounds 
under Assumption 1 only become −11.31% ≤ ACE ≤ 72.60%, where inequalities (4.1) and 
(4.2) yield the same bounds. While the bounds under Assumption 1 only do not give enough 
information about ACE, adding Assumptions 3.2 and 4.2 greatly improves the bounds. 
5. Noncompliance by receiving no treatment 
While noncompliance by switching the treatment was discussed in Sections 3 and 4, this 
section discusses noncompliance by receiving no treatment, which means that non-
compliers receive no treatment. In this type of noncompliance, subjects who are allocated to 
R = 2 take the value of X = 0 or 2 (and not X = 1) and those who are allocated to R = 1 take 
the value of X = 0 or 1 (and not X = 2). Thus, p0|2 + p2|2 = 1 and p0|1 + p1|1 = 1. The 
derivations of equations and inequalities in this section are similar to those in Sections 3 and 
4, and can be achieved straightforwardly by replacing x = 1, 2 in Sections 3 and 4 to x = 0, 1 
and x = 0, 2. Thus, they are omitted. 
5.1 Biases of estimates 
By following a similar discussion to Section 3, we show that the ITT and PP estimators 
generally yield biased estimates of ACE. Unfortunately, the IV estimator cannot be defined 
in this type of noncompliance.  
To express the biases of ITT and PP estimators, we introduce the following bias factors 
instead of ǂr and ǃr in Section 3: 
Ǆ ≡ E(YX=2|X = 2, R = 2) – E(YX=2|X = 0, R = 2), 
ǅ ≡ E(YX=1|X = 1, R = 1) – E(Y X=1|X = 0, R = 1). 
Similar to ǂr and ǃr, Ǆ and ǅ are also confounding effects. Ǆ is interpreted as a confounding 
effect that would arise from comparisons of those with X = 2 versus those with X = 0 for the 
test treatment group. When Ǆ > 0, E(YX=2|X = 2, R = 2) > E(YX=2|X = 0, R = 2), which means 
that the subjects who received the test treatment tend to take larger outcome values than 
those who received no treatment. Conversely, when Ǆ < 0, E(YX=2|X = 2, R = 2) < E(YX=2|X = 
0, R = 2), which means that the subjects who received the test treatment tend to take smaller 
outcome values than those who received no treatment. Whether subjects in the test 
treatment group actually receive the treatment is randomly determined when Ǆ = 0. ǅ is 
interpreted using a similar process in the control group. 
Biases of ITT and PP estimators can be explained in a similar manner to Section 3, using Ǆ 
and ǅ. Because E(YX=2) and E(YX=1) are expressed as E(YX=2) = E22 – Ǆp0|2 and E(YX=1) = E11 – 
ǅp0|1, the ITT estimator is given by: 
www.intechopen.com
 
Health Management – Different Approaches and Solutions 
 
324 
ITT = ACE + {Ǆ – (E22 – E02)}p0|2 – {ǅ – (E11 – E01)}p0|1. 
Therefore, the ITT estimator is generally a biased estimator of ACE, and can be unbiased 
when Ǆ = E22 – E02 and ǅ = E11 – E01, i.e., E(YX=r|X = 0, R = r) = E(YX=0|X = 0, R = r) for r = 1, 
2. This equation indicates that the ITT estimate can be unbiased when no effect of the 
treatments exists against no treatment for all subjects (under the sharp null hypothesis:  
YX=x = YX=0 for all subjects, where x = 1, 2). 
The PP estimator is given by: 
PP = ACE + Ǆp0|2 – ǅp0|1. 
Thus, the PP estimate can be unbiased when Ǆ = 0 and ǅ = 0, implying that whether subjects 
receive the assigned treatment is randomly determined (no confounder exists between X 
and Y). 
In contrast to the case of noncompliance by switching the treatment, it may be difficult to 
know the signs of biases of ITT and PP estimates. 
5.2 Bounds on average causal effect 
We extend the bounds concept introduced in Section 4.1 to the case of noncompliance by 
receiving no treatment. 
The bounds under Assumption 1 only are as follows: 
 (E22p2|2 + K0p0|2) – (E11p1|1 + K1p0|1) ≤ ACE ≤ (E22p2|2 + K1p0|2) – (E11p1|1 + K0p0|1), (5.1) 
where [K0, K1] is a finite range of outcome Y. In the case of a binary outcome, this inequality 
is simplified to: 
P12|2 + P01|1 – 1 ≤ ACE ≤ 1 – P02|2 – P11|1. 
As in Section 4.1, the MTR and MTS assumptions and these reverse assumptions can be 
applied to obtain bounds on ACE with narrower widths. For example, for (s, t) = (2, 0), 
Assumption 2.1 is YX=2 ≥ YX=0, which means that a subject takes a larger outcome value if 
he/she received the test treatment than if he/she received no treatment. This holds when it 
is apparent that the test treatment has a positive effect compared with no treatment. The 
similar interpretation is given for (s, t) = (1, 0) (YX=1 ≥ YX=0) in place of the test treatment to 
the control. 
Under Assumptions 1 and 2.1, the lower bound of E(YX=x) becomes E(YX=x) ≥ E(Y|R = x) for 
x = 1, 2, which is derived using t = 0 in Assumption 2.1. Likewise, E(YX=x) ≤ E(Y|R = x) 
under Assumptions 1 and 2.2. Although these bounds of E(YX=x) do not give a bound on 
ACE in contrast to that in Section 4.1.2, Assumption 2.1 can derive the following bounds by 
combination with inequality (5.1)1: 
E(Y|R = 2) – (E11p1|1 + K1p0|1) ≤ ACE ≤ (E22p2|2 + K1p0|2) – E(Y|R = 1). 
Similar to Assumptions 3.1 and 3.2, in the case of a binary outcome variable, we can make 
weaker assumptions that derive the same bounds as those under Assumptions 2.1 and 2.2, 
using the principal stratification approach. In the case of noncompliance by receiving no 
treatment, four types of potential outcomes, based on principal stratification, are re-
                                                 
1 If (s, t) = (2, 1) in Assumption 2.1 is used as in Section 4.1, the lower bound on ACE is improved to 0. 
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defined as follows: doomed {YX=x = 1, YX=0 = 1}, which consists of subjects who always 
experience the event, regardless of whether they receive the assigned treatment; 
preventive {YX=x = 0, YX=0 = 1}, which consists of subjects who do not experience the event 
when they receive the assigned treatment but do when they receive no treatment; 
causative {YX=x = 1, YX=0 = 0}, which consists of subjects who experience the event when 
they receive the assigned treatment, but not when they receive no treatment; and immune 
{YX=x = 0, YX=0 = 0}, which consists of subjects who never experience the event, regardless 
of whether they receive the assigned treatment. In the definition, x = 2 for the test 
treatment group (R = 2) and x = 1 for the control group (R = 1). Similar to Section 4.1.2, 
Assumption 2.1 implies that no preventive subject exists, and Assumption 2.2 implies that 
no causative subject exists. 
Under this definition of principal strata, alternative assumptions of Assumptions 2.1 and 2.2 
are as follows: 
ASSUMPTION 3.3 
 Pr(YX=x = 1, YX=0 = 0|X = R = x) ≥ Pr(YX=x = 0, YX=0 = 1|X = R = x) for x = 1, 2. 
ASSUMPTION 3.4 
 Pr(YX=x = 1, YX=0 = 0|X = R = x) ≤ Pr(YX=x = 0, YX=0 = 1|X = R = x) for x = 1, 2. 
Assumption 3.3 implies that the number of causative subjects is not less than the number of 
preventive subjects, and Assumption 3.4 implies that the number of causative subjects is not 
more than the number of preventive subjects, within both assigned groups. Thus, these 
Assumptions are weaker than assumptions 2.1 and 2.2. Nevertheless, they can give the same 
bounds as those under Assumptions 2.1 and 2.2. 
The MTS and RMTS (Assumptions 4.1 and 4.2) can also be applied to the case of 
noncompliance by receiving no treatment. For example, for (s, t) = (2, 0) and r = 2, 
Assumption 4.1 is E(YX=x|X = 2, R = 2) ≥ E(YX=x|X = 0, R = 2), which means that subjects 
who received the assigned test treatment (i.e., compliers) tend to have larger outcome values 
than those who received no treatment (i.e., non-compliers) for the test treatment group. 
Under Assumptions 1 and 4.1, the upper bound of E(YX=x) becomes E(YX=x) ≥ Exx (E(YX=x) ≤ 
Exx under Assumptions 1 and 4.2) for x = 1, 2. Thus, the combination with inequality (5.1) 
derives bounds on ACE of: 
(E22p2|2 + K0p0|2) – E11 ≤ ACE ≤ E22 – (E11p1|1 + K0p0|1). 
When both MTR and MTS hold, the bounds on ACE are: 
E(Y|R = 2) – E11 ≤ ACE ≤ E22 – E(Y|R = 1), 
because E(Y|R = x) ≤ E(YX=x) ≤ Exx for x = 1, 2. When both RMTR and RMTS hold, these 
signs of inequalities for E(YX=x) are reversed. 
Finally, we note that the MC and RMC (Assumptions 5.1 and 5.2), which derive the same 
bounds as those under the MTS and RMTS (Assumptions 4.1 and 4.2), are changed as 
follows for the case of noncompliance by receiving no treatment: 
ASSUMPTION 5.3: Monotone confounding (MC) 
 Both E(Y|X = R = x, Z = z) and Pr(X = x|R = x, Z = z) are non-decreasing or non-increasing in 
z for x = 1, 2 and all r, and the components of Z are independent of each other. 
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ASSUMPTION 5.4: Reverse monotone confounding (RMC) 
 One of E(Y|X = R = x, Z = z) and Pr(X = x|R = x, Z = z) is non-decreasing and the other is non-
increasing in z for x = 1, 2 and all r, and the components of Z are independent of each other. 
In some actual situations, assumptions presented in this section may hold for one of the test 
treatment and control groups but not for the other. In such cases, the assumptions can be 
applied only to one group. This example is introduced in the next sub-section. 
5.3 Application 
We apply the assumptions and bounds presented in Section 5.2 to the CDP trial introduced 
in Section 1 (Table 1). R represents the assigned group (R = 2 for the clofibrate group and  
R = 1 for the placebo group), and X is the compliance status (X = 2 for compliers in the 
clofibrate group, X = 1 for compliers in the placebo group, and X = 0 for non-compliers). 
Here, compliers and non-compliers are patients receiving more or less than 80% of the 
assigned treatment, respectively. Y is the incidence of deaths (Y = 1 for dead and Y = 0 for 
alive). Again, we note that ITT and PP analyses yielded ITT = 194/1065 – 523/2695 = –1.19% 
and PP = 106/708 – 274/1813 = –0.14%, respectively. 
As in Section 4.3, it is necessary to discuss whether the assumptions hold. There may be a 
placebo effect, but it is not thought that the proportion of deaths will increase by receiving 
the placebo. Thus, Assumptions 2.2 (RMTR) and 3.4 can be assumed for (s, t) = (1, 0) and x = 
1. However, a preventive effect of clofibrate may not be present (i.e., these assumptions may 
not be assumed for (s, t) = (2, 0) and x = 2) because of side-effects. The World Health 
Organization (WHO) has reported that in a large randomized trial, there were 25% more 
deaths in the clofibrate group than in the comparable high serum cholesterol control group 
(WHO, 1980). Because it is not clear whether the clofibrate has a positive or negative effect, 
we cannot assume the MTR or RMTR (and Assumption 3.3 or 3.4) for the clofibrate group. 
Relating to the patients in this trial, health-oriented subjects might tend not to die and be more 
likely to comply with the assigned treatment, compared with subjects not concerned about 
their health. Under this observation, the RMTS (Assumption 4.4) would hold for both assigned 
groups. However, we note that some researchers may criticize this because some patients 
might not receive the treatment due to side-effects. In such a case, the RMTS may not hold for 
the clofibrate group. Nevertheless, we assume the RMTS for both assigned groups for 
illustrative purposes. Assumption 1 would hold because this trial was a double-blinded trial. 
The arguments presented above demonstrate that the RMTR and RMTS can be assumed for 
the placebo group. Therefore, the bounds of E(YX=1) are E11 ≤ E(YX=1) ≤ E(Y|R = 1), which 
yield 15.11% ≤ E(YX=1) ≤ 19.41%. For the clofibrate group, the RMTS is assumed and then the 
bounds of E(YX=2) are E22 ≤ E(YX=2) ≤ E22p2|2 + K1p0|2 for K1 = 1, which yields 14.97% ≤ E(YX=2) 
≤ 43.47%. In conclusion, the bounds on ACE are −4.43% ≤ ACE ≤ 28.36%. Unfortunately, we 
cannot conclude whether clofibrate is effective. However, the bounds improve those under 
Assumption 1 only: −32.94% ≤ ACE ≤ 33.31%, especially the lower bound. 
6. Monotone instrumental variable 
Sections 3-5 assumed the IV assumption (Assumption 1). As mentioned in Section 2, 
however, this assumption often may not hold in unblinded trials, in which subjects are 
aware of the assigned treatment and this knowledge may affect the potential outcomes. In 
the MRFIT (Section 4.3), subjects would have been aware of their assigned group because it 
was an unblinded trial, and thus the intervention itself might have evoked a psychological 
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response. Furthermore, in addition to smoking cessation counseling, the intervention 
consisted of dietary advice to reduction blood cholesterol and hypertension medication. 
These interventions might also have influenced the incidence of CHD independent of 
smoking status. Thus, in this section, we relax the IV assumption to the following monotone 
instrumental variable (MIV) assumption (Manski & Pepper, 2000, 2009): 
ASSUMPTION 6.1: Monotone instrumental variable (MIV) 
 E(YX=x|R = 2) ≥ E(YX=x|R = 1). 
The MIV assumption is only the replacement of equality in the IV assumption with 
inequality, and means that the values of potential outcomes for subjects assigned to R = 2 
are overall larger than those assigned to R = 1. For example, consider an unblinded trial to 
compare a new treatment with a standard treatment, where the outcome is a measure such 
that a larger value is better for the subject’s health. In such a trial, subjects may think that the 
new treatment is more effective than the standard treatment, and this thinking may give rise 
to better results for subjects assigned to the new treatment than those assigned to the 
standard treatment; this indicates that the MIV holds. 
We can also consider the following reverse MIV (RMIV) assumption: 
ASSUMPTION 6.2: Reverse monotone instrumental variable (RMIV)  
E(YX=x|R = 2) ≤ E(YX=x|R = 1). 
We discuss the bounds on ACE under Assumptions 6.1 and 6.2 instead of Assumption 1. 
Noncompliance by switching the treatment (as in Sections 4) is discussed in Section 6.1, and 
noncompliance by receiving no treatment (as in Section 5) is discussed in Section 6.2. The 
derivations of inequalities in this section are outlined in Section 8.3. 
6.1 Noncompliance by switching the treatment 
The bounds introduced in Section 4 are extended to those under the MIV and RMIV 
(Assumptions 6.1 and 6.2). Under the MIV and RMIV, the bounds on ACE are: 
 (E21p2|1 + K0p1|1) − (E12p1|2 + K1p2|2) ≤ ACE ≤ (E22p2|2 + K1p1|2) − (E11p1|1 + K0p2|1), (6.1) 
 (E22p2|2 + K0p1|2) − (E11p1|1 + K1p2|1) ≤ ACE ≤ (E21p2|1 + K1p1|1) − (E12p1|2 + K0p2|2). (6.2) 
These inequalities correspond to inequalities when a or b in max{a, b} and min{a, b} in 
inequality (4.1) are used. Therefore, the MIV and RMIV assumptions yield bounds on ACE 
with the same or broader width in comparison with the bounds under the IV assumption. 
Even under the MIV (or RMIV) assumption, but not IV assumption, we can derive bounds 
on ACE with narower widths by applying assumptions in Section 4.2 (Chiba, 2010c). Each 
combination of the MIV or RMIV and the MTR or RMTR derives the improved lower or 
upper bounds on ACE in Table 3. Likewise, each combination of the MIV or RMIV and the 
MTS or RMTS derives the improved lower or upper bounds on ACE in Table 4. 
 
Assumptions Improved bound on ACE 
MIV + MTR ACE ≥ max{−ITT, 0}
RMIV + MTR ACE ≥ max{ITT, 0}
MIV + RMTR ACE ≤ min{ITT, 0}
RMIV + RMTR ACE ≤ min{−ITT, 0}
Table 3. Improved bound on ACE under the MIV or RMIV and the MTR or RMTR, where 
ITT ≡ E(Y|R = 2) – E(Y|R = 1). 
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Assumptions Improved bound on ACE 
MIV + MTS ACE ≤ E22 – E11 
RMIV + MTS ACE ≤ E21 – E12 
MIV + RMTS ACE ≥ E21 – E12 
RMIV + RMTS ACE ≥ E22 – E11 
Table 4. Improved bound on ACE under the MIV or RMIV and the MTS or RMTS. 
Eight lower or upper bounds in Tables 3 and 4 yield the same or broader bounds as those 
under the IV assumption. Note that we can use Assumptions 3.1 and 3.2 instead of the MTR 
and RMTR (Assumptions 2.1 and 2.2), respectively, and Assumptions 5.1 and 5.2 instead of 
the MTS and RMTS (Assumptions 4.1 and 4.2), respectively. Further combinations of the 
above bounds can derive further improved bounds; for example, max{−ITT, 0} ≤ ACE ≤ PP 
under the MIV, MTR and MTS assumptions. 
For illustration, we apply the bounds presented here to the MRFIT (Table 2), in which  
the IV assumption may not hold, as discussed above. Because the intervention consisted 
of dietary advice and hypertension medication as well as the therapy itself that might 
have evoked a psychological response, the potential incidence of CHD for subjects 
assigned to the test group might have been reduced, compared with subjects assigned to 
the control group. This observation shows that Assumption 6.2 (RMIV: E(YX=x|R = 2) ≤ 
E(YX=x|R = 1)) is reasonable. Additionally, as discussed in Section 4.3, the RMTR (or 
Assumption 3.2) and RMTS are reasonable assumptions in this trial. In conclusion, the 
RMIV, RMTR and RMTS can be assumed, and then bounds on ACE become PP ≤ ACE ≤ 
min{−ITT, 0}, which yield −0.92% ≤ ACE ≤ 0%. In comparison with the IV (plus RMTR and 
RMTS) in Section 4.2 (−0.92% ≤ ACE ≤ −0.13%), the lower bound is the same but the upper 
bound is larger. 
6.2 Noncompliance by receiving no treatment 
The bounds introduced in Section 5 are extended to those under the MIV and RMIV 
(Assumptions 6.1 and 6.2). Under these assumptions, the bounds on ACE are: 
 K0 − K1 ≤ ACE ≤ (E22p2|2 + K1p0|2) − (E11p1|1 + K0p0|1), (6.3) 
 (E22p2|2 + K0p0|2) − (E11p1|1 + K1p0|1) ≤ ACE ≤ K1 − K0, (6.4) 
respectively. The upper bound in inequality (6.3) is equal to that in inequality (5.1) and the 
lower bound in inequality (6.4) is equal to that in inequality (5.1). Unfortunately, the 
respective lower and upper bounds in inequalities (6.3) and (6.4) do not give any 
information. 
As discussed in the above sub-section, by combining the MTR (or RMTR) and MTS (or 
RMTS), the bounds on ACE can be improved. Table 5 summarizes the bounds under the 
MIV or RMIV and the MTR and RMTR, and Table 6 summarizes those under the MIV or 
RMIV and the MTS and RMTS. The bounds in Tables 5 and 6 include K0 or K1, which is the 
finite range of Y. Specifically, in Table 6, the lower or upper bounds are not improved even 
when the MTS or RMTS is added. Thus, the bounds may not be greatly improved. However, 
further combinations of these assumptions can remove K0 and K1 from one of the lower and 
upper bounds. Such bounds are summarized in Table 7. 
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Assumptions Bounds on ACE 
MIV + MTR E(Y|R = 1) − (E22p2|2 + K1p0|2) ≤ ACE ≤ (E22p2|2 + K1p0|2) − E(Y|R = 1) 
RMIV + MTR E(Y|R = 2) − (E11p1|1 + K1p0|1) ≤ ACE ≤ K1 – (E02p0|2 + K0p2|2) 
MIV + RMTR K0 − (E02p0|2 + K1p2|2) ≤ ACE ≤ E(Y|R = 2) − (E11p1|1 + K0p0|1) 
RMIV + RMTR (E22p2|2 + K0p0|2) – E(Y|R = 1) ≤ ACE ≤ E(Y|R = 1) − (E22p2|2 + K0p0|2) 
Table 5. Bounds on ACE under the MIV or RMIV and the MTR or RMTR2. 
 
Assumptions Bounds on ACE 
MIV + MTS K0 – K1 ≤ ACE ≤ E22 – (E11p1|1 + K0p0|1) 
RMIV + MTS (E22p2|2 + K0p0|2) – E11 ≤ ACE ≤ K1 – K0 
MIV + RMTS K0 – K1 ≤ ACE ≤ (E22p2|2 + K1p0|2) – E11 
RMIV + RMTS E22 – (E11p1|1 + K1p0|1) ≤ ACE ≤ K1 – K0 
Table 6. Bounds on ACE under the MIV or RMIV and the MTS or RMTS. 
 
Assumptions Bounds on ACE 
MIV + MTR + MTS E(Y|R = 1) − (E22p2|2 + K1p0|2) ≤ ACE ≤ E22 − E(Y|R = 1) 
RMIV + MTR + MTS E(Y|R = 2) − E11 ≤ ACE ≤ K1 – (E02p0|2 + K0p2|2) 
MIV + RMTR + RMTS K0 − (E02p0|2 + K1p2|2) ≤ ACE ≤ E(Y|R = 2) − E11 
RMIV + RMTR + RMTS E22 – E(Y|R = 1) ≤ ACE ≤ E(Y|R = 1) − (E22p2|2 + K0p0|2) 
Table 7. Bounds on ACE under some combinations of assumptions3. 
For illustration, we apply the bounds presented here to the CDP trial (Table 1). Although the 
IV (Assumption 1) would hold in this trial because it was a double-blinded trial, we here 
relax this assumption to the MIV and RMIV (Assumptions 6.1 and 6.2), and yield bounds on 
ACE under both assumptions. As discussed in Section 5.3, we assume the RMTS for the 
clofibrate group and the RMTR and RMTS for the placebo group. Then, under the MIV, the 
bounds of E(YX=2) and E(YX=1) are K0 ≤ E(YX=2) ≤ E22p2|2 + K1p0|2 and E11 ≤ E(YX=1) ≤ E02p0|2 + 
K1p2|2, respectively, where K0 = 0 and K1 = 1 because Y is binary. These bounds yield bounds 
on ACE of −74.74% ≤ ACE ≤ 28.36%. Likewise, under the RMIV, the bounds on ACE become 
−4.43% ≤ ACE ≤ 90.05%, because E22 ≤ E(YX=2) ≤ K1 and E22p2|2 + K0p0|2 ≤ E(YX=1) ≤ E(Y|R = 
1). Unfortunately, these bounds have a very broad width, and thus they do not provide 
enough information about treatment effects of clofibrate. 
7. Conclusion 
This chapter has presented bounds on ACE in randomized trials with noncompliance. 
Although the results presented here are relevant to the causal differences, they can also be 
readily applied to the causal risk ratio when the outcome is binary. 
                                                 
2 If (s, t) = (2, 1) in the MTR and RMTR (Assumptions 2.1 and 2.2) is used, the lower bound is 0 under the 
MTR and the upper bound is 0 under the RMTR. 
3 If (s, t) = (2, 1) in the MTR and RMTR (Assumptions 2.1 and 2.2) is additionally used, a candidate of the 
lower bound is 0 under the MTR and that of the upper bound is 0 under the RMTR. 
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It is generally thought that the ITT analysis is likely to yield a downwardly biased estimate 
of causal effects (Sheiner & Rubin, 1995), whereas the PP analysis is likely to yield an 
upwardly biased estimate (Lewis & Machine, 1993). Thus, the ACE probably exists between 
the results of the ITT and PP analyses. As shown in Section 4.1, this is true under IV + MTR 
+ MTS or under IV + RMTR + RMTS for noncompliance by switching the treatment. 
However, as shown in Sections 5 and 6, we cannot be certain that this is true when 
noncompliance is due to receiving no treatment and/or the IV assumption does not hold. 
Thus, investigators should not simply conclude that the ACE exists between the results of 
the ITT and PP analyses. Unfortunately, no standard method currently exists for estimating 
the ACE in randomized trials with noncompliance issues. Investigators should consider 
whether the assumptions presented in this chapter are valid and then yield bounds on ACE 
using the methodology described herein. 
The needs from further methodologies in this field are three-fold. The first is to find weaker 
assumptions than those given here, which nevertheless can derive the same bounds. The 
second is to make assumptions that can derive the bounds with a narrower width, which are 
still reasonable in some situations. The ideal is to make a reasonable assumption that can 
give a point estimator. The third and final need is to extend the discussions in this chapter to 
more complex situations: for example, two types of noncompliance in this chapter may 
occur simultaneously, and more than two arms may be compared (Cheng & Small, 2006). 
The other recent interest in causal inference is statistical analysis concerning the role of an 
intermediate variable between a particular treatment and outcome (Rubin, 2004; Joffe et al., 
2007; VanderWeele, 2008b). Investigators are often interested in understanding how the 
effect of a treatment on an outcome may be mediated through an intermediate variable. For 
example, in the MRFIT, this implies that investigators are interested in how the effect of a 
multifactor intervention program on CHD mortality may be mediated through the smoking 
status 1 year after entry, rather than the effect of the smoking status 1 year after entry on 
CHD mortality. Such statistical analyses are closely related to issues of inference with a 
surrogate marker and issues of post-randomization selection bias and truncation-by-death 
(Zhang & Rubin, 2003; Chiba & VanderWeele, 2011). Further methodological research is 
needed to answer these issues. 
8. Appendix: Derivations of equations and inequalities 
This section outlines the derivations of the equations and inequalities presented in Sections 
3, 4 and 6, which are outlined in Sections 8.1, 8.2 and 8.3, respectively. 
8.1 Derivations of equations in Section 3 
Equation (3.1) can be derived as follows: 
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The first equation holds by Assumption 1, and the third equation is derived by substituting 
E(YX=2|X = 1, R = r) = E(YX=2|X = 2, R = r) – ǂr and applying the consistency assumption: 
E(YX=2|X = 2, R = r) = E(Y|X = 2, R = r) (= E2r). A similar calculation derives equation (3.2). 
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To derive equation (3.3), we consider the difference between E(Y|R = 2) and E(YX=2) and 
between E(Y|R = 1) and E(YX=1). The former difference derives: 
.)}({
)1()(
)()(E)2|(E
2|122222
2|2222|1212
2|1222
2,1
2|22
pEE
pEpE
pEpEYRY
x
xxX
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 





 
By a similar calculation, the latter difference becomes E(Y|R = 1) – E(YX=1) = {ǃ1 – (E21 – 
E11)}p2|1. The difference between these equations derives equation (3.3). 
The derivation of equation (3.5) is as follows. Simple algebra, p2|r × equation (3.1) plus p1|r × 
equation (3.2), yields p2|rACE + E(YX=1) = E(Y|R = r) – (ǂr – ǃr)p1|rp2|r. The difference 
between this equation with r = 2 and that with r = 1 is: 
(p2|2 – p2|1)ACE = E(Y|R = 2) – E(Y|R = 1) – (ǂ2 – ǃ2)p1|2p2|2 + (ǂ1 – ǃ1)p1|1p2|1. 
This equation implies equation (3.5) for p2|2 ≠ p2|1. 
8.2 Derivations of inequalities in Section 4 
Inequality (4.1) can be derived as presented below. By substituting K0 ≤ E(YX=x|X = x*, R = r) 
≤ K1 for x ≠ x* and E(YX=x|X = x*, R = r) = E(Y|X = x, R = r) (= Exr) for x = x* (consistency 
assumption) into: 
 
,)|*Pr()*,|(E)|(E
2,1*


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x
xXxX rRxXrRxXYrRY
 (8.1) 
we obtain: 
 Exrpx|r + K0px*|r ≤ E(YX=x | R = r) ≤ Exrpx|r + K1px*|r (8.2) 
for x ≠ x*. Because E(YX=x) = E(YX= x|R = r) by Assumption 1, the bounds of E(YX= x) become: 
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for x ≠ x*. The difference between the lower and upper bounds of this inequality for x = 1, 2 
is inequality (4.1). 
Inequality (4.3) can be also derived using equation (8.1). Assumption 2.1 implies that 
E(YX=2|X = x, R = r) ≥ E(YX=1|X = x, R = r). Thus, by substituting this inequality with x = 1 
into equation (8.1), we obtain: 
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(8.3)
 
and thus E(YX=2) ≥ max{E(Y|R = 1), E(Y|R = 2)}. Similarly, E(YX=1) ≤ min{E(Y|R = 1), E(Y|R 
= 2)} by substituting E(YX=2|X = 2, R = r) ≥ E(YX=1|X = 2, R = r) into equation (8.1). The 
difference between them is inequality (4.3). 
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In the case of a binary outcome variable, inequality (4.3) can also be derived under 
Assumption 3.1. By adding Pr(YX=2 = 1, YX=1 = 1|X = x, R = r) on both sides of the inequality in 
Assumption 3.1: Pr(YX=2 = 1, YX=1 = 0|X = x, R = r) ≥ Pr(YX=2 = 0, YX=1 = 1|X = x, R = r), we 
obtain Pr(YX=2 = 1|X = x, R = r) ≥ Pr(YX=1 = 1|X = x, R = r). Because this inequality is a binary 
outcome version of E(YX=2|X = x, R = r) ≥ E(YX=1|X = x, R = r), inequality (4.3) is derived. 
Inequality (4.4) can be derived as follows. Substituting E(YX=2|X = 2, R = r) ≥ E(YX=2|X = 1, 
R = r) (x = 2 and (s, t) = (2, 1) in Assumption 4.1) into equation (8.1) yields: 
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(8.4)
 
and thus E(YX=2) ≤ min{E21, E22}. Similarly, E(YX=1) ≥ max{E11, E12} by substituting E(YX=1|X = 
2, R = r) ≥ E(YX=1|X = 1, R = r) (x = 1 and (s, t) = (2, 1) in Assumption 4.1) into equation (8.1). 
The difference between them is inequality (4.4). 
Inequality (4.4) can also be derived under Assumption 5.1. To prove this, we need the 
following lemma (Esary et al., 1967): 
LEMMA 1 
Let f and g be functions with n real-valued arguments such that both f and g are non-decreasing or non-
increasing in each of their arguments. If Z = (Z1, …, Zn) is a multivariate random variable with n 
components such that each component is independent of the other components, then Cov{f(Z), g(Z)} ≥ 0. 
Let fr(Z) = E(Y|X = 2, R = r, Z = z), gr(Z) = Pr(X = 2|R = r, Z = z) and FZ|R=r denote the 
cumulative distribution function of Z conditional on R = r. Then, by Lemma 1, we obtain: 
,0)}(),({Cov)}({E)}({E)}()({E 

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if both fr(Z) and gr(Z) are non-decreasing or non-increasing in z and the components of Z are 
independent. Thus, using the assumption that YX=x is independent from X given R and Z, 
the following inequality is derived: 
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The second equation holds because E(YX=2|X = 1, R = r, Z = z) = E(YX=2|X = 2, R = r, Z = z) = 
E(Y|X = 2, R = r, Z = z) by the independency and consistency assumptions. The fourth 
inequality holds because 1 – gr(Z) is non-increasing when gr(Z) is non-decreasing. The fifth 
and sixth equations hold because: 
).|2Pr()|Pr(),|2Pr()}({E
|
rRXrRzZzZrRXZg
z
rF rRZ
  
A similar calculation derives E(YX=1|X = 2, R = r) ≥ E(Y|X = 1, R = r). The inequalities 
derived here are the same as those in Assumption 4.1. Therefore, inequality (4.4) can be 
derived under Assumption 5.1. 
8.3 Derivations of inequalities in Section 6 
E(YX=x) can be expressed as E(YX=x) = E(YX=x|R = 1)Pr(R = 1) + E(YX=x|R = 2)Pr(R = 2). 
Therefore, 
 E(YX=x|R = 1) ≤ E(YX=x) ≤ E(YX=x|R = 2) (8.5) 
under Assumption 6.1 (MIV: E(YX=x|R = 1) ≥ E(YX=x|R = 0)). All bounds under the MIV are 
derived based on inequality (8.5), while those under the IV (Assumption 1) are based on 
E(YX=x) = E(YX=x|R = r). This is why inequality (6.1) corresponds to it when a or b in max{a, 
b} and min{a, b} in inequality (4.1) is used. This is also similar under the RMIV (Assumption 
6.2), and then inequality (6.2) and the bounds in Tables 3 and 4 also correspond to those 
when a or b in max{a, b} and min{a, b} in the bounds presented in Section 4.1 are used. 
Therefore, the derivations of bounds in Section 6.1 are simple. Inequality (6.1) is derived by 
the combination of inequalities (8.2) and (8.5). 
In Table 3, ACE ≥ max{−ITT, 0} under the MIV and MTR is derived as follows. Because E(YX=2) 
≥ E(YX=2|R = 1) from inequality (8.5), E(YX=2) ≥ E(Y|R = 1) from inequality (8.3) with r = 1. 
Likewise, E(YX=1) ≤ E(Y|R = 2) by E(YX=1) ≤ E(YX=1|R = 2) and the MTR (Assumption 2.1). The 
difference between these inequalities derives ACE ≥ −ITT. Additionally, the MTR derives  
ACE = E(YX=1) − E(YX=0) ≥ 0 directly. The other bounds in Table 3 can be derived in a similar way. 
In Table 4, ACE ≤ E22 – E11 under the MIV and MTS is derived as follows. Because  
E(YX=2) ≤ E(YX=2|R = 2) from inequality (8.5), E(YX=2) ≤ E22 from inequality (8.4) with r = 2. 
Likewise, E(YX=1) ≥ E11 by E(YX=1) ≥ E(YX=1|R = 1) and the MTS (Assumption 4.1). The 
difference between these inequalities derives ACE ≤ E22 – E11. The other bounds in Table 4 
can be derived in a similar way. 
The inequalities in Section 6.2 can be derived in straightforward manner as the derivations 
of those in Section 6.1 by replacing x = 1, 2 in Section 6.1 to x = 0, 1 and x = 0, 2, although 
they may be somewhat complex. 
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